Literature DB >> 20712327

Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines.

X H Ma1, R Wang, C Y Tan, Y Y Jiang, T Lu, H B Rao, X Y Li, M L Go, B C Low, Y Z Chen.   

Abstract

Multitarget agents have been increasingly explored for enhancing efficacy and reducing countertarget activities and toxicities. Efficient virtual screening (VS) tools for searching selective multitarget agents are desired. Combinatorial support vector machines (C-SVM) were tested as VS tools for searching dual-inhibitors of 11 combinations of 9 anticancer kinase targets (EGFR, VEGFR, PDGFR, Src, FGFR, Lck, CDK1, CDK2, GSK3). C-SVM trained on 233-1,316 non-dual-inhibitors correctly identified 26.8%-57.3% (majority >36%) of the 56-230 intra-kinase-group dual-inhibitors (equivalent to the 50-70% yields of two independent individual target VS tools), and 12.2% of the 41 inter-kinase-group dual-inhibitors. C-SVM were fairly selective in misidentifying as dual-inhibitors 3.7%-48.1% (majority <20%) of the 233-1,316 non-dual-inhibitors of the same kinase pairs and 0.98%-4.77% of the 3,971-5,180 inhibitors of other kinases. C-SVM produced low false-hit rates in misidentifying as dual-inhibitors 1,746-4,817 (0.013%-0.036%) of the 13.56 M PubChem compounds, 12-175 (0.007%-0.104%) of the 168 K MDDR compounds, and 0-84 (0.0%-2.9%) of the 19,495-38,483 MDDR compounds similar to the known dual-inhibitors. C-SVM was compared to other VS methods Surflex-Dock, DOCK Blaster, kNN and PNN against the same sets of kinase inhibitors and the full set or subset of the 1.02 M Zinc clean-leads data set. C-SVM produced comparable dual-inhibitor yields, slightly better false-hit rates for kinase inhibitors, and significantly lower false-hit rates for the Zinc clean-leads data set. Combinatorial SVM showed promising potential for searching selective multitarget agents against intra-kinase-group kinases without explicit knowledge of multitarget agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20712327     DOI: 10.1021/mp100179t

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  10 in total

Review 1.  Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system.

Authors:  Vertika Gautam; Anand Gaurav; Neeraj Masand; Vannajan Sanghiran Lee; Vaishali M Patil
Journal:  Mol Divers       Date:  2022-07-11       Impact factor: 3.364

2.  Evolution of Support Vector Machine and Regression Modeling in Chemoinformatics and Drug Discovery.

Authors:  Raquel Rodríguez-Pérez; Jürgen Bajorath
Journal:  J Comput Aided Mol Des       Date:  2022-03-19       Impact factor: 4.179

Review 3.  Getting the most out of PubChem for virtual screening.

Authors:  Sunghwan Kim
Journal:  Expert Opin Drug Discov       Date:  2016-08-05       Impact factor: 6.098

4.  A two-step target binding and selectivity support vector machines approach for virtual screening of dopamine receptor subtype-selective ligands.

Authors:  Jingxian Zhang; Bucong Han; Xiaona Wei; Chunyan Tan; Yuzong Chen; Yuyang Jiang
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

5.  Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression method.

Authors:  Hongying Du; Zhide Hu; Andrea Bazzoli; Yang Zhang
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

6.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery.

Authors:  Feng Zhu; Zhe Shi; Chu Qin; Lin Tao; Xin Liu; Feng Xu; Li Zhang; Yang Song; Xianghui Liu; Jingxian Zhang; Bucong Han; Peng Zhang; Yuzong Chen
Journal:  Nucleic Acids Res       Date:  2011-09-24       Impact factor: 16.971

7.  Identification of a Selective G1-Phase Benzimidazolone Inhibitor by a Senescence-Targeted Virtual Screen Using Artificial Neural Networks.

Authors:  Alan E Bilsland; Angelo Pugliese; Yu Liu; John Revie; Sharon Burns; Carol McCormick; Claire J Cairney; Justin Bower; Martin Drysdale; Masashi Narita; Mahito Sadaie; W Nicol Keith
Journal:  Neoplasia       Date:  2015-09       Impact factor: 5.715

8.  Clustered distribution of natural product leads of drugs in the chemical space as influenced by the privileged target-sites.

Authors:  Lin Tao; Feng Zhu; Chu Qin; Cheng Zhang; Shangying Chen; Peng Zhang; Cunlong Zhang; Chunyan Tan; Chunmei Gao; Zhe Chen; Yuyang Jiang; Yu Zong Chen
Journal:  Sci Rep       Date:  2015-03-20       Impact factor: 4.379

9.  De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.

Authors:  Robert Urich; Grant Wishart; Michael Kiczun; André Richters; Naomi Tidten-Luksch; Daniel Rauh; Brad Sherborne; Paul G Wyatt; Ruth Brenk
Journal:  ACS Chem Biol       Date:  2013-03-27       Impact factor: 5.100

Review 10.  When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease.

Authors:  Santosh R D'Mello
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.